Javelin Pharmaceuticals, Inc. hosted a conference call today featuring CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, discussing the Company's quarterly results for the period ending March 31, 2009.

Rodman & Renshaw Capital Group, Inc. will hosts a conference call discussing it's investor presentation regarding the proposed combination with Cowen Group, Inc. The call is hosted by Michael Lacovara and David Horin, Rodman’s Chief Executive Officer and Chief Financial Officer, respectively.

Javelin Pharmaceuticals, Inc. hosted a conference call today featuring CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, discussing the Company's quarterly results for the period ending September 30, 2008.

Javelin Pharmaceuticals, Inc. hosts a conference call, with CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, discussing the Company's quarterly results for the period ending June 30, 2008.

Zangani interviews Raymond King, Senior Manager - Global Business Development for TSX Group, a North American exchange and the world's largest exchange for small and mid cap companies.

Raymond discusses the TSX business model, and talks about the value proposition it offers both American and international companies, including those from Italy.

Javelin Pharmaceuticals, Inc. hosts a conference call, with CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, discussing the Company's quarterly results for the period ending March 31, 2008.

About Javelin Pharmaceuticals, Inc.:

Javelin is a specialty pharmaceutical company that applies proprietary technologies to develop new drugs and improved formulations of existing drugs for pain management. Specialty pharmaceutical analysts from six investment firms cover Javelin Pharmaceuticals, Inc. Javelin's headquarters are located in Cambridge, Massachusetts with European offices in Cambridge, England and Cologne, Germany. For additional information, visit www.javelinpharmaceuticals.com.

Javelin Pharmaceuticals, Inc. hosts a conference call, with Dr. Daniel B. Carr, CEO and CMO, and Stephen J. Tulipano, CPA, CFO, discussing the Company's annual results for the period ending December 31, 2007.

About Javelin Pharmaceuticals, Inc.:

Javelin is a specialty pharmaceutical company that applies proprietary technologies to develop new drugs and improved formulations of existing drugs for pain management. Specialty pharmaceutical analysts from six investment firms cover Javelin Pharmaceuticals, Inc. Javelin's headquarters are located in Cambridge, Massachusetts with European offices in Cambridge, England and Cologne, Germany. For additional information, visit www.javelinpharmaceuticals.com.

Listen to Webcast Interview

Zangani Investor Communityâ„¢ interviews Rhonda Greenapple, president & founder of Reimbursement Intelligence. Rhonda discusses how changes to the Medicare benefit impact utilization of biologics, injectables and other high cost products.

Listen to Webcast Interview

Learn how to help bring your product to approval.

Zangani Investor Communityâ„¢ interviews Rhonda Greenapple, president & founder of Reimbursement Intelligence. Rhonda answers critical questions for all Biotech or specialty product organizations bringing a product to market.

Reimbursement Intelligence is a full-service consulting company that focuses on defining reimbursement strategies and business planning for biocapital companies.

Today Dr. Daniel B. Carr, CEO and CMO, and Stephen J. Tulipano, CPA, CFO, hosted a conference call discussing the Company's quarterly results for the period ending September 30, 2007.

Javelin Participants:

Dr. Daniel B. Carr, CEO and CMO; Fred Mermelstein, Ph.D., President; Stephen J. Tulipano, CPA, CFO; David B. Bernstein, Esq., General Counsel and Chief IP Counsel; Dr. Curtis Wright, IV, MPH, EVP, Risk Management and Regulatory Affairs and Rick Pierce, VP Investor Relations.

Zangani Investor Community(TM) interviews Rhonda Greenapple, president & founder of Reimbursement Intelligence. Rhonda provides an overview of the formulary process and answers critical questions for all biotech or specialty product organizations bringing a product to market. Listen in to learn how to help bring your product to approval.

Reimbursement Intelligence is a full-service consulting company that focuses on defining reimbursement strategies and business planning for biocapital companies.

Javelin Pharmaceuticals CEO, Dr. Daniel B. Carr, provided a corporate overview at the recent BioCentury NewsMakers Conference in New York. Dr. Carr provided updates on the recent progress of Dylojectâ„¢ and PMI-150 (intranasal ketamine), two of Javelin's late stage pain care product candidates.

GeoPharma, Inc. hosted a conference call discussing results for the first fiscal quarter ended June 30, 2007 on Tuesday, August 14, 2007 at 11:30 a.m. (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore- Falcone. The Company has released the Company's operating results, available here:

GeoPharma Reports Q1 2008 Results

The Zangani Investor Communityâ„¢ interviewed Dr. Antonio Graziano from the Dept. of Experimental Health and the Dept. of Dentistry at the Second University of Naples.

Dr. Graziano lends some of his insight regarding stem cell research, and the impact on the economics of developing countries. He also discusses the current state of stem cell research in Italy and Europe, and possible routes of improvement.

The Zangani Investor Communityâ„¢ interviewed David Miller, President and Editor-in-Chief of Biotech Stock Research LLC. David discusses various aspects of Biotech Stock Research, as well as some of the current happenings in the biotech industry.

David D. Miller is an acknowledged expert on biotech investing. With a background as a company CEO, technical analyst, and market commentator, he provides a uniquely unabashed analysis of the sector and companies in his coverage universe. Mr. Miller has been quoted in nearly every major US newspaper, has appeared on financial television multiple times, and authored a chapter entitled “The Keys to Biotech Investing” in the popular Wiley Financial Press book Master Traders (2006, edited by Fari Hamzei).

Dr. Gurel discusses some of the emerging technologies and major trends impacting investors in the biopharma and medical technology sectors.

Dr. Ogan Gurel is chairman of the Aesis Group, which provides consulting services to companies and investment firms in the life sciences and healthcare sectors. He is also Chief Medical Officer of BlueBob Analytics and an Adjunct Associate Professor of Bioengineering at the University of Illinois – Chicago. Gurel was previously CEO of Duravest, a publicly traded Chicago investment company that initiates and develops next-generation medical technologies. Previous to Duravest, he was a vice president and medical director at Sg2, a health-care intelligence think tank and consultancy serving hospitals and health systems and an associate at Booz Allen Hamilton. He can be e-mailed at gurel@aesisgroup.com.

Chet Paulson, Chairman of the Paulson Investment Company, was interviewed today by the Zangani Investor Communityâ„¢.

Chet discusses the Paulson Investment group and describes some of the many successful stock offerings that they have managed.

The Paulson Investment group is the Northwest's largest independent brokerage firm and a leading investor banker for emerging companies.

Dr. Daniel Carr, CEO and CMO, and members of Javelin's senior management hosted a call on three recent milestones as well as progress in the clinical development of PMI-150 (intranasal ketamine).

Recent milestones include recently reported top line results for Javelin's Phase 3 pivotal trial of Rylomine (intranasal morphine), the ten year extension of European patent protection for Dyloject (injectable diclofenac) to 2024, and the selection of Javelin Pharmaceuticals by Russell Research for the Russell 2000®, 3000®, Micro-cap(TM) and Global Indexes.

Accompanying presentation is available by clicking here.

Today GeoPharma, Inc. hosted a conference call discussing March 31, 2007 fiscal year end earning results with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. The Company has released earnings, available here:

GeoPharma Reports Record Revenues and Record Earnings

GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com, www.hoodiadexl10.com and www.onlineihp.com .

Dr. Carr discusses the three late stage product candidates in development: Dylojectâ„¢ (diclofenac sodium, injectable), Rylomineâ„¢ (intranasal morphine) and PMI-150 (intranasal ketamine), and a general overview of the pharmaceutical company.

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market.